VA Office of Research and Development
Glioblastoma is an infiltrating tumor that is difficult to visualize in surgery and on standard images. A special pH (acid-base) related magnetic resonance imaging (MRI) has been developed to better see infiltrating tumor. In this safety study, the investigators will carry out increased levels of pH based resections of infiltrating tumor to assess the tolerability in VA populations.
Current standard of care therapy and all FDA approved adjuvant therapy for glioblastoma continue to provide less than 12 months of progression free survival (PFS) and less than 24 months of overall survival (OS). There is an extreme need for any novel therapy against glioblastoma that increases progression free survival and overall survival in patients diagnosed with this invasive form of cancer. A significant reason for such a poor prognosis is the infiltrative nature of this tumor in non-enhancing regions (NE) beyond the central contrast-enhancing (CE) portion of tumor, which is difficult to…
Inclusion Criteria: * Ability to provide written informed consent * Karnofsky Performance Scale (KPS) of 70 or higher * Suspected, newly diagnosed or recurrent IDH wild type WHO IV glioblastoma presenting as an intra-axial * Expansile contrast-enhancing mass without evidence of metastatic disease Exclusion Criteria: * Diagnostic uncertainty such as history of extracranial malignancy or autoimmune disease * Medical conditions prohibiting anesthesia or surgery * Tumors involving eloquent brain areas as defined by MRI signal * primary motor cortex, primary sensory cortex, sensorimotor fibers,…
This will require a chemical exchange saturation transfer MRI followed by surgical resection based on this MRI.
Arctuva estimate
Verify or correct the compensation shown for this listing.